应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
PFE 辉瑞
盘后交易 03-28 17:48:18 EDT
27.75
-0.03
-0.11%
盘后
27.76
+0.01
+0.04%
17:48 EDT
最高
28.12
最低
27.72
成交量
4,042万
今开
27.82
昨收
27.78
日振幅
1.44%
总市值
1,571亿
流通市值
1,569亿
总股本
56.63亿
成交额
11.27亿
换手率
0.71%
流通股本
56.54亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
更新 2-美国疾病预防控制中心提醒医疗服务提供者注意脑膜炎球菌疾病的增加
Reuters · 04:19
更新 2-美国疾病预防控制中心提醒医疗服务提供者注意脑膜炎球菌疾病的增加
辉瑞上涨1.22%,报28.12美元/股
金融界 · 01:43
辉瑞上涨1.22%,报28.12美元/股
CDE受理安斯泰来和辉瑞的EV+帕博利珠单抗一线治疗晚期膀胱癌sBLA
美通社 · 03-28 14:24
CDE受理安斯泰来和辉瑞的EV+帕博利珠单抗一线治疗晚期膀胱癌sBLA
辉瑞上涨1.21%,报27.93美元/股
金融界 · 03-28 00:42
辉瑞上涨1.21%,报27.93美元/股
辉瑞公司董事长艾伯乐:辉瑞会一直在中国投资发展
中国新闻网 · 03-27 15:04
辉瑞公司董事长艾伯乐:辉瑞会一直在中国投资发展
辉瑞(PFE.US)及阿斯利康(AZN.US)拟在华推出多个新药或适应症申请
阿斯达克财经 · 03-26 14:41
辉瑞(PFE.US)及阿斯利康(AZN.US)拟在华推出多个新药或适应症申请
尹力分别会见诺华集团、辉瑞公司、丹纳赫集团负责人
新京报网 · 03-25
尹力分别会见诺华集团、辉瑞公司、丹纳赫集团负责人
辉瑞宣布将40%的研发费用投入癌症创新疗法研究
钛媒体 · 03-25
辉瑞宣布将40%的研发费用投入癌症创新疗法研究
更新 1-BioNTech 因拖欠 COVID 疫苗版税而收到美国机构通知
Reuters · 03-25
更新 1-BioNTech 因拖欠 COVID 疫苗版税而收到美国机构通知
辉瑞艾伯乐:AI价值不可限量,将颠覆性改变医药行业的未来
澎湃新闻 · 03-25
辉瑞艾伯乐:AI价值不可限量,将颠覆性改变医药行业的未来
生物科技产业天花板,那些年薪过亿的CEO是怎么诞生的?
氨基观察 · 03-25
生物科技产业天花板,那些年薪过亿的CEO是怎么诞生的?
盈利暴跌后,BioNTech 寄希望于癌症药物的上市
Reuters · 03-20
盈利暴跌后,BioNTech 寄希望于癌症药物的上市
辉瑞逾28亿英镑出售英国健康产品公司Haleon股份
观点新媒体 · 03-20
辉瑞逾28亿英镑出售英国健康产品公司Haleon股份
辉瑞拟以 7.85美元/股增发Haleon股票,持股降至22.6%
智通财经 · 03-19
辉瑞拟以 7.85美元/股增发Haleon股票,持股降至22.6%
辉瑞公司以 39 亿美元出售感舒雅生产商 Haleon 的股份
Reuters · 03-19
辉瑞公司以 39 亿美元出售感舒雅生产商 Haleon 的股份
辉瑞(PFE.US)CD3/BCMA双抗拟优先审评!用于复发或难治性多发性骨髓瘤治疗
智通财经 · 03-18
辉瑞(PFE.US)CD3/BCMA双抗拟优先审评!用于复发或难治性多发性骨髓瘤治疗
辉瑞将出售赫力昂约8%股份 持股比例减至约24%
金融界 · 03-18
辉瑞将出售赫力昂约8%股份 持股比例减至约24%
辉瑞(PFE.US)计划出售25亿美元Haleon(HLN.US)股票 持股比例降至24%
智通财经 · 03-18
辉瑞(PFE.US)计划出售25亿美元Haleon(HLN.US)股票 持股比例降至24%
消费保健公司Haleon称辉瑞拟将持股比例降至约24%
金融界 · 03-18
消费保健公司Haleon称辉瑞拟将持股比例降至约24%
BUZZ-第一大股东辉瑞将减持股份,英国 Haleon 公司股价下跌
Reuters · 03-18
BUZZ-第一大股东辉瑞将减持股份,英国 Haleon 公司股价下跌
暂无数据
公司概况
公司名称:
辉瑞
所属市场:
NYSE
上市日期:
--
主营业务:
辉瑞公司于1942年6月2日根据特拉华州法律成立。公司是一家以研究为基础的全球性生物制药公司。公司运用科学和全球资源,通过发现、开发、制造和分销保健产品(包括创新药物和疫苗),为人们带来延长和显著改善其生活的疗法。公司在发达国家和新兴市场开展工作,致力于促进健康、预防、治疗和治愈这个时代最令人恐惧的疾病。公司与医疗保健提供商、政府和当地社区合作,支持并扩大在全球范围内获得可靠、负担得起的医疗保健服务。
发行价格:
--
{"stockData":{"symbol":"PFE","market":"US","secType":"STK","nameCN":"辉瑞","latestPrice":27.75,"timestamp":1711656000000,"preClose":27.78,"halted":0,"volume":40420318,"hourTrading":{"tag":"盘后","latestPrice":27.76,"preClose":27.75,"latestTime":"17:48 EDT","volume":2890404,"amount":80209482.737868,"timestamp":1711662480303},"delay":0,"floatShares":5653844760,"shares":5662541291,"eps":0.367372,"marketStatus":"盘后交易","marketStatusCode":4,"change":-0.03,"latestTime":"03-28 17:48:18 EDT","open":27.82,"high":28.12,"low":27.72,"amount":1126813292.172564,"amplitude":0.014399,"askPrice":27.8,"askSize":1000,"bidPrice":27.73,"bidSize":302,"shortable":3,"etf":0,"ttmEps":0.367372,"exchange":"NYSE","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1711670400000},"adr":0,"listingDate":-819144000000,"adjPreClose":27.78,"adrRate":0,"dividendRate":0.059099,"preHourTrading":{"tag":"盘前","latestPrice":27.83,"preClose":27.78,"latestTime":"09:29 EDT","volume":1768567,"amount":49131422.638418995,"timestamp":1711632599074},"postHourTrading":{"tag":"盘后","latestPrice":27.76,"preClose":27.75,"latestTime":"17:48 EDT","volume":2890404,"amount":80209482.737868,"timestamp":1711662480303},"volumeRatio":1.247215,"optionData":{"bulkOrders":[{"symbol":"PFE","call":false,"expireDate":1715313600000,"strike":"25.0","timestamp":1711634735457,"price":0.23000000417232513,"volume":8383,"amount":192809,"type":"+"},{"symbol":"PFE","call":false,"expireDate":1715313600000,"strike":"25.0","timestamp":1711634735457,"price":0.2199999988079071,"volume":8382,"amount":184404,"type":"+"}]}},"requestUrl":"/m/hq/s/PFE/tweets","defaultTab":"tweets","newsList":[{"id":"2423125514","title":"更新 2-美国疾病预防控制中心提醒医疗服务提供者注意脑膜炎球菌疾病的增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2423125514","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2423125514?lang=zh_cn&edition=full","pubTime":"2024-03-29 04:19","pubTimestamp":1711657176,"startTime":"0","endTime":"0","summary":"今年 10 月,美国食品和药物管理局批准了 辉瑞公司的 疫苗 Penbraya,这是第一种可预防五个脑膜炎球菌群的疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2423146739","title":"辉瑞上涨1.22%,报28.12美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2423146739","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2423146739?lang=zh_cn&edition=full","pubTime":"2024-03-29 01:43","pubTimestamp":1711647830,"startTime":"0","endTime":"0","summary":"3月29日,辉瑞(PFE)盘中上涨1.22%,截至01:43,报28.12美元/股,成交4.65亿美元。财务数据显示,截至2023年12月31日,辉瑞收入总额584.96亿美元,同比减少41.7%;归母净利润21.19亿美元,同比减少93.25%。大事提醒:5月7日,辉瑞将披露2024财年一季报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/29014340044493.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2422913574","title":"CDE受理安斯泰来和辉瑞的EV+帕博利珠单抗一线治疗晚期膀胱癌sBLA","url":"https://stock-news.laohu8.com/highlight/detail?id=2422913574","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2422913574?lang=zh_cn&edition=full","pubTime":"2024-03-28 14:24","pubTimestamp":1711607040,"startTime":"0","endTime":"0","summary":"此次用于一线治疗的联合用药疗法sBLA是基于一项3期临床试验EV-302的结果。安全性结果与之前报告的联合疗法结果一致,未发现新的安全性问题。密切监测患者的皮肤反应。对疑似SJS或TEN或严重的皮肤反应,应立即停用enfortumab vedotin并考虑转诊至专业护理。安斯泰来警戒声明 本新闻稿中,有关当前计划、估计、战略和信念以及其他非历史事实的陈述,均为关于安斯泰来未来表现的前瞻性陈述。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4373421_ZH73421_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422094331","title":"辉瑞上涨1.21%,报27.93美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2422094331","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2422094331?lang=zh_cn&edition=full","pubTime":"2024-03-28 00:42","pubTimestamp":1711557742,"startTime":"0","endTime":"0","summary":"3月28日,辉瑞(PFE)盘中上涨1.21%,截至00:42,报27.93美元/股,成交3.53亿美元。财务数据显示,截至2023年12月31日,辉瑞收入总额584.96亿美元,同比减少41.7%;归母净利润21.19亿美元,同比减少93.25%。大事提醒:5月7日,辉瑞将披露2024财年一季报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/28004240025063.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2422793793","title":"辉瑞公司董事长艾伯乐:辉瑞会一直在中国投资发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2422793793","media":"中国新闻网","top":-1,"share":"https://www.laohu8.com/m/news/2422793793?lang=zh_cn&edition=full","pubTime":"2024-03-27 15:04","pubTimestamp":1711523099,"startTime":"0","endTime":"0","summary":"3月24日下午举行了“大健康产业专题研讨会”,辉瑞公司董事长、首席执行官艾伯乐在“对话”环节的发言中表示:辉瑞非常重视科学创新,希望和中国的科研机构,以及中国的生物制药生态系统结成紧密的纽带。对于辉瑞公司下一阶段在中国市场的投资运营计划,艾伯乐表示,辉瑞会一直在中国投资发展,因为中国是一个非常有前景的市场。艾伯乐提出,治疗癌症和艾滋病的药物,以及与人类精神卫生相关的药物是制药产业重点关注的领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032715061187bb2bba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032715061187bb2bba&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422530326","title":"辉瑞(PFE.US)及阿斯利康(AZN.US)拟在华推出多个新药或适应症申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2422530326","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2422530326?lang=zh_cn&edition=full","pubTime":"2024-03-26 14:41","pubTimestamp":1711435260,"startTime":"0","endTime":"0","summary":"辉瑞董事长兼首席执行官艾伯乐在北京出席“投资中国”活动致词时提到,对中国的创新药物开发前景感兴趣,计划明年前在中国提交17个新药或适应症申请。阿斯利康首席执行官苏博科亦称,目前研发管线逾200个项目,预计未来5年将在中国推出约100个新药及适应症申请。另外,艾伯乐较早时表示,中国市场潜力巨大,存在着许多机会,相信在数年内中国就会成为生物科技创新的尖端。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20211125141320348_s.jpeg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20211125141320348_s.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1337065/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2422104425","title":"尹力分别会见诺华集团、辉瑞公司、丹纳赫集团负责人","url":"https://stock-news.laohu8.com/highlight/detail?id=2422104425","media":"新京报网","top":-1,"share":"https://www.laohu8.com/m/news/2422104425?lang=zh_cn&edition=full","pubTime":"2024-03-25 21:32","pubTimestamp":1711373520,"startTime":"0","endTime":"0","summary":"据北京日报消息,3月25日下午,市委书记尹力分别会见了瑞士诺华集团全球首席执行官万思瀚、美国辉瑞公司董事长兼首席执行官艾伯乐和美国丹纳赫集团全球总裁兼首席执行官毕睿宁。尹力介绍了北京市经济社会发展及居民健康状况。艾伯乐表示,中国医药健康产业市场规模巨大,北京创新能力强、营商环境一流,为医药企业提供了广阔机遇,辉瑞公司愿同北京在创新研发、应对公共卫生挑战等领域进一步深化拓展合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403252135467a4ee819&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403252135467a4ee819&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422238519","title":"辉瑞宣布将40%的研发费用投入癌症创新疗法研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2422238519","media":"钛媒体","top":-1,"share":"https://www.laohu8.com/m/news/2422238519?lang=zh_cn&edition=full","pubTime":"2024-03-25 20:05","pubTimestamp":1711368335,"startTime":"0","endTime":"0","summary":"钛媒体App 3月25日消息,辉瑞董事长兼首席执行官艾伯乐博士(Albert Bourla)在中国发展高层论坛2024上强调了辉瑞对于创新与合作的重视,并表示辉瑞用于推进癌症创新疗法相关的研发投入已占比整体研发投入的大约40%。目前辉瑞已进入中国35年。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032520054087b2fcdf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032520054087b2fcdf&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422592487","title":"更新 1-BioNTech 因拖欠 COVID 疫苗版税而收到美国机构通知","url":"https://stock-news.laohu8.com/highlight/detail?id=2422592487","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2422592487?lang=zh_cn&edition=full","pubTime":"2024-03-25 18:47","pubTimestamp":1711363674,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) (在第 2-3 段增加了细节和背景) 路透社3月25日 - BioNTech 周一称,美国国立卫生研究院已向这家德国公司发出通知,要求其支付与COVID-19疫苗相关的版税和其他款项。BioNTech公司与美国制药巨头辉瑞公司(Pfizer )合作生产的COVID-19疫苗引发了特许权使用费支付纠纷。但该公司表示,它不同意美国国立卫生研究院的立场,并打算对所有违约指控进行抗辩。美国国立卫生研究院的发言人没有立即回应路透社的置评请求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422828594","title":"辉瑞艾伯乐:AI价值不可限量,将颠覆性改变医药行业的未来","url":"https://stock-news.laohu8.com/highlight/detail?id=2422828594","media":"澎湃新闻","top":-1,"share":"https://www.laohu8.com/m/news/2422828594?lang=zh_cn&edition=full","pubTime":"2024-03-25 18:17","pubTimestamp":1711361820,"startTime":"0","endTime":"0","summary":"辉瑞希望与中国政府进行合作,实现双赢。艾伯乐指出,生物制药创新是非常有前景的,当前人们对于药物的创新需求非常大。艾伯乐认为,包括像癌症、艾滋病,还包括其他的一些疾病,现在是全世界最大的杀手。艾伯乐谈到,生物科技在不断地发展,其他方面的技术也在与时俱进,AI对所有人来说都是颠覆性,将完全改变医药行业的未来。辉瑞设计6000个分子,然后很快地进行测试和验证。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403251817508b60a75d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403251817508b60a75d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422558821","title":"生物科技产业天花板,那些年薪过亿的CEO是怎么诞生的?","url":"https://stock-news.laohu8.com/highlight/detail?id=2422558821","media":"氨基观察","top":-1,"share":"https://www.laohu8.com/m/news/2422558821?lang=zh_cn&edition=full","pubTime":"2024-03-25 11:48","pubTimestamp":1711338482,"startTime":"0","endTime":"0","summary":"CEO的薪酬,总是会成为谈资,尤其是生物科技行业。因为生物科技行业诞生了诸多巨头,而这些巨头领导者的薪酬往往不低。尤其在海外,跨国大药企的CEO,天价年薪是常态。2023年,艾伯维CEORichard Gonzalez,总薪酬是2570万美金;吉利德CEO Daniel O'Day年薪达到了2260万美元,强生CEO Joaquin Duato总薪酬更是高达2840万美元...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OpPH-RLvq4UG27EC6TWYG2RnLrNxHYDWPrtPHS-Icb0v8AA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OpPH-RLvq4UG27EC6TWYG2RnLrNxHYDWPrtPHS-Icb0v8AA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240325A03I4Q00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240325A03I4Q00","is_publish_highlight":false,"gpt_icon":0},{"id":"2420671912","title":"盈利暴跌后,BioNTech 寄希望于癌症药物的上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2420671912","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2420671912?lang=zh_cn&edition=full","pubTime":"2024-03-20 18:15","pubTimestamp":1710929704,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 路透社柏林3月20日 - 德国生物技术公司(BioNTech )与辉瑞公司(Pfizer )合作生产的COVID-19疫苗在流感大流行期间被广泛使用。这家总部位于美因茨的公司公布的收入为 38.19 亿欧元,比 2022 年下降了四分之三以上,净利润为 9.303 亿欧元,比上年同期下降了 90%。BioNTech公司在一份声明中表示,2024年的目标收入为25亿至31亿欧元,这主要取决于监管方面的发展和COVID-19疫苗的吸收情况。声明还说,该公司的目标是在 2026 年首次推出肿瘤药物,并在 2030 年之前批准十项适应症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2420756822","title":"辉瑞逾28亿英镑出售英国健康产品公司Haleon股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2420756822","media":"观点新媒体","top":-1,"share":"https://www.laohu8.com/m/news/2420756822?lang=zh_cn&edition=full","pubTime":"2024-03-20 10:27","pubTimestamp":1710901654,"startTime":"0","endTime":"0","summary":"观点网讯:3月20日,美国药企辉瑞宣布出售其持有的英国消费者健康产品公司Haleon部分股份,成功套现逾28亿英镑。此次交易中,辉瑞配售了6.96亿股Haleon股份,每股定价为3.08英镑。同时,辉瑞还出售了9800万份Haleon美国预托证券(ADR),每份ADR作价7.85美元,相当于两股Haleon股份。作为交易的一部分,Haleon公司回购了价值3.15亿英镑的股份。资料显示,辉瑞本次减持后,持有股权降至23%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403201028178b4a33d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403201028178b4a33d5&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420214233","title":"辉瑞拟以 7.85美元/股增发Haleon股票,持股降至22.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2420214233","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2420214233?lang=zh_cn&edition=full","pubTime":"2024-03-19 16:58","pubTimestamp":1710838684,"startTime":"0","endTime":"0","summary":"此次发行约7.9055亿股Haleon普通股,其中包括5.94亿股普通股和约1.9655亿股美国存托股票形式的普通股,每股ADS代表两股普通股。Haleon没有出售或发行任何证券,也不会从全球要约中获得任何净收益。Haleon应向辉瑞支付的股票回购价格为每股普通股3.08英镑,等于全球要约中每股普通股的发行价。在全球发行和股票回购之后,辉瑞在Haleon的持股比例将从32%降至约22.6%。一段时间以来,葛兰素史克一直在减持所持Haleon股份。辉瑞也开始抛售所持Haleon股份。","market":"us","thumbnail":"https://static.tigerbbs.com/203ed3b07d0328bcae45acd59054d614","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/203ed3b07d0328bcae45acd59054d614"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1088366.html","is_publish_highlight":true,"gpt_icon":1},{"id":"2420219010","title":"辉瑞公司以 39 亿美元出售感舒雅生产商 Haleon 的股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2420219010","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2420219010?lang=zh_cn&edition=full","pubTime":"2024-03-19 16:19","pubTimestamp":1710836381,"startTime":"0","endTime":"0","summary":"辉瑞此前持股 32%,第二大股东葛兰素史克 持股 4.2%。重要原因 这是辉瑞自Haleon于 2022 年从葛兰素史克剥离并上市以来首次出售其股份。辉瑞去年表示,计划在数月内以 \"缓慢而有条不紊 \"的方式减持股份。与此同时,最初持有 12.9% 股份的葛兰素史克也在去年出售了股份,最后一次出售是在今年 1 月。这比海伦周一披露的 6.3 亿股销售 。下一步行动 股权出售和回购预计将于 3 月 21 日完成,辉瑞的股票将有 90 天的锁定期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2420422854","title":"辉瑞(PFE.US)CD3/BCMA双抗拟优先审评!用于复发或难治性多发性骨髓瘤治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2420422854","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2420422854?lang=zh_cn&edition=full","pubTime":"2024-03-18 19:16","pubTimestamp":1710760565,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,3月18日,据CDE官网显示,拟将辉瑞CD3/BCMA双抗Elranatamab上市申请纳入优先审评,用于既往接受过至少三种治疗的复发或难治性多发性骨髓瘤成人患者的治疗。Elranatamab是全球获批上市的第二款BCMA/CD3双特异性抗体,于去年8月14日获美国FDA加速批准,治疗既往接受过至少4种疗法的复发性或难治性多发性骨髓瘤成人患者。据Insight数据库显示,当前全球共26款CD3/BCMA双抗在研,除了已上市的Teclistamab和Elranatamab(辉瑞)之外,Linvoseltamab也已经申报上市,另有2款处于III期临床阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1087927.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2420844282","title":"辉瑞将出售赫力昂约8%股份 持股比例减至约24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2420844282","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2420844282?lang=zh_cn&edition=full","pubTime":"2024-03-18 16:48","pubTimestamp":1710751704,"startTime":"0","endTime":"0","summary":"英国消费保健巨头赫力昂(Haleon)周一表示,辉瑞公司将出售其在该公司的约6.3亿股股份,将其持股减少到24%左右。辉瑞目前持有赫力昂的32%股份,该公司去年5月宣布,计划在几个月内以“缓慢而有条理”的方式减持股权。赫力昂在一份声明中表示,辉瑞出售其股份的价格预计将在3月19日左右公布,届时将完成簿记程序。赫力昂于2022年7月从英国制药巨头葛兰素史克分拆出来,生产Sensodyne牙膏和Advil止痛药等家用品牌。自那以来,葛兰素史克一直在减持其在该公司的股份,最后一次减持是在今年1月,使其持股比例降至4.2%。\n\n\r\n 责任编辑:史文瑞","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/18164839889207.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2420419584","title":"辉瑞(PFE.US)计划出售25亿美元Haleon(HLN.US)股票 持股比例降至24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2420419584","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2420419584?lang=zh_cn&edition=full","pubTime":"2024-03-18 16:27","pubTimestamp":1710750450,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,辉瑞计划出售所持英国消费保健公司Haleon6.3亿股股票,价值约20亿英镑。据了解,辉瑞是Haleon最大股东,持股比例达32%。根据一份声明,出售和回购将使辉瑞在Haleon的持股比例从32%降至24%左右。Haleon是由葛兰素史克和辉瑞的消费保健部门合并而成。在维权投资者Elliott Investment Management的压力下,葛兰素史克将消费保健部门分拆出来,专注于制药和疫苗业务。辉瑞也开始抛售所持Haleon股份。辉瑞此前曾表示,希望专注于制药创新。截至发稿,Haleon盘前跌超2%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1087738.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2420449217","title":"消费保健公司Haleon称辉瑞拟将持股比例降至约24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2420449217","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2420449217?lang=zh_cn&edition=full","pubTime":"2024-03-18 16:10","pubTimestamp":1710749426,"startTime":"0","endTime":"0","summary":"消费保健公司haleon周一表示,辉瑞将出售其持有的约6.3亿股公司股份,从而将持股比例降至约24%。辉瑞目前持有Haleon32%的股份,去年曾表示计划在几个月内以“缓慢而有条不紊”的方式减持股份。Haleon在一份声明中称,每股要约价格预计将在3月19日前后公布,届时将完成建账程序。该公司还将从场外市场向辉瑞回购价值约3.15亿英镑的股票。该公司于上月宣布,鉴于对其产品的强劲需求以及在减少债务方面取得的进展,计划今年回购5亿英镑的股票。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403181615438b423bd7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403181615438b423bd7&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420446777","title":"BUZZ-第一大股东辉瑞将减持股份,英国 Haleon 公司股价下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2420446777","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2420446777?lang=zh_cn&edition=full","pubTime":"2024-03-18 16:07","pubTimestamp":1710749269,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 3月18日 - ** 消费者保健公司海伦 股价早盘下跌2.3%,报314.75便士** 公司称 (link) 第一大股东美国制药商辉瑞 将出售HLN约24%的股份;出价将于3月19日或前后公布 ** 截至 HLN 上次收盘价 322.30 便士,6.3 亿股的出售价值约为 20.3 亿英镑。** 此外,HLN 还将从辉瑞公司回购价值 3.15 亿英镑的场外股份。** 截至上次收盘,股价在过去 12 个月中上涨了 1.2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pfizer.com","stockEarnings":[{"period":"1week","weight":0.0029},{"period":"1month","weight":0.0221},{"period":"3month","weight":-0.0351},{"period":"6month","weight":-0.1625},{"period":"1year","weight":-0.3053},{"period":"ytd","weight":-0.0351}],"compareEarnings":[{"period":"1week","weight":0.0052},{"period":"1month","weight":0.034},{"period":"3month","weight":0.0975},{"period":"6month","weight":0.2238},{"period":"1year","weight":0.3225},{"period":"ytd","weight":0.1007}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"辉瑞公司于1942年6月2日根据特拉华州法律成立。公司是一家以研究为基础的全球性生物制药公司。公司运用科学和全球资源,通过发现、开发、制造和分销保健产品(包括创新药物和疫苗),为人们带来延长和显著改善其生活的疗法。公司在发达国家和新兴市场开展工作,致力于促进健康、预防、治疗和治愈这个时代最令人恐惧的疾病。公司与医疗保健提供商、政府和当地社区合作,支持并扩大在全球范围内获得可靠、负担得起的医疗保健服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.00126},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.007167},{"month":3,"riseRate":0.613636,"avgChangeRate":0.016011},{"month":4,"riseRate":0.613636,"avgChangeRate":0.021662},{"month":5,"riseRate":0.5,"avgChangeRate":0.00626},{"month":6,"riseRate":0.5,"avgChangeRate":0.002739},{"month":7,"riseRate":0.477273,"avgChangeRate":0.010684},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.000087},{"month":9,"riseRate":0.454545,"avgChangeRate":0.004027},{"month":10,"riseRate":0.659091,"avgChangeRate":0.014878},{"month":11,"riseRate":0.704545,"avgChangeRate":0.030213},{"month":12,"riseRate":0.5,"avgChangeRate":0.0093}],"exchange":"NYSE","name":"辉瑞","nameEN":"Pfizer"},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.3","shortVersion":"4.22.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供辉瑞(PFE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"辉瑞,PFE,辉瑞股票,辉瑞股票老虎,辉瑞股票老虎国际,辉瑞行情,辉瑞股票行情,辉瑞股价,辉瑞股市,辉瑞股票价格,辉瑞股票交易,辉瑞股票购买,辉瑞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供辉瑞(PFE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}